Monte Rosa Therapeutics, INC

Monte Rosa Therapeutics reported strong Q2 2026 progress with key clinical trial activations and enrollment completions, alongside a robust cash runway extending into 2029, though net loss widened.

Monte Rosa Therapeutics, Inc. announced the results of its 2026 Annual Meeting of Stockholders, including the election of three Class II directors and the ratification of its independent auditor.

Monte Rosa Therapeutics reported Q1 2026 results, highlighting significant clinical program advancements and a strong cash position expected to fund operations into 2029.

Monte Rosa Therapeutics announced positive clinical data for multiple programs, strengthened its balance sheet with a $345 million financing, and extended its cash runway into 2029.

Monte Rosa Therapeutics announces the retirement of its SVP, Corporate Controller, and Principal Accounting Officer, Edmund Dunn, and the appointment of Matthew Bowen as his successor.

Monte Rosa Therapeutics announced the pricing of an underwritten public offering of common stock and pre-funded warrants, expecting to raise approximately $281.6 million in net proceeds to fund its pipeline and platform development.

Monte Rosa Therapeutics reported its second-quarter 2026 financial results, highlighting increased research and development expenses and a net loss, while maintaining substantial cash reserves and significant collaboration revenue from ongoing partnerships.

Monte Rosa Therapeutics reported a significant decrease in collaboration revenue and an increase in operating expenses for Q1 2026, leading to a net loss, while also highlighting substantial cash reserves and ongoing strategic partnerships.

Monte Rosa Therapeutics reported a net income of $7.5 million for the nine months ended September 30, 2025, driven by a new $120 million upfront payment from Novartis and progress in its clinical pipeline.

Monte Rosa Therapeutics reports a significant shift to net income in Q2 2025, driven by collaboration revenue, while advancing its molecular glue degrader pipeline.

Monte Rosa Therapeutics reports a net income of $46.9 million for Q1 2025, primarily driven by collaboration revenue from Roche and Novartis.

Monte Rosa Therapeutics reported its Q3 2024 financial results, showcasing progress in clinical trials and a significant collaboration agreement with Novartis.

Monte Rosa Therapeutics reported significant progress in its molecular glue degrader pipeline, including positive clinical data for MRT-2359 and MRT-8102, and strengthened its financial position with a $323.8 million capital raise.

Monte Rosa Therapeutics reports financial results for 2024, highlights clinical progress, and enters a strategic licensing agreement with Novartis for its VAV1-directed MGD program.

Monte Rosa Therapeutics' 10-K filing outlines its capital structure, including common and preferred stock, pre-funded warrants, and various anti-takeover provisions.

Markus Warmuth, President & CEO and a Director of Monte Rosa Therapeutics, Inc., sold 9,500 shares of common stock on July 16, 2026 for $23.18 per share.

Jennifer Champoux, Chief Operating Officer of Monte Rosa Therapeutics, Inc., sold 4,351 shares of common stock on July 15, 2026 for $23.38 per share.

Sharon Townson, Chief Scientific Officer at Monte Rosa Therapeutics, Inc., executed a series of transactions involving the purchase and sale of company common stock on July 6, 2026, under a pre-established Rule 10b5-1 trading plan.

Ali Behbahani, a Director at Monte Rosa Therapeutics, Inc., reported transactions involving common stock on July 1, 2026, primarily through investment entities.

Filip Janku, Chief Medical Officer of Monte Rosa Therapeutics, Inc., executed a Rule 10b5-1 trading plan transaction involving the acquisition and disposition of common stock.

Filip Janku, Chief Medical Officer of Monte Rosa Therapeutics, Inc., executed a Rule 10b5-1 trading plan transaction on June 29, 2026, involving the acquisition of 6,000 shares and the disposition of 6,000 shares.

Monte Rosa Therapeutics has filed a definitive proxy statement with the SEC regarding its upcoming shareholder meeting.

Monte Rosa Therapeutics will hold its 2025 Annual Meeting of Stockholders virtually on June 13, 2025, to elect directors and ratify the appointment of its independent accounting firm.

Monte Rosa Therapeutics has filed a definitive proxy statement with the SEC.

Monte Rosa Therapeutics will hold its 2024 Annual Meeting of Stockholders virtually on June 12, 2024, to elect directors and ratify the appointment of its independent accounting firm.

New Enterprise Associates 17, L.P. and affiliated entities have filed an amendment to their Schedule 13D, reporting a beneficial ownership of 7.9% of Monte Rosa Therapeutics, Inc. common stock.

New Enterprise Associates 17, L.P. and its affiliates reported a decrease in their beneficial ownership of Monte Rosa Therapeutics, Inc. common stock to 9.6% due to an increase in the issuer's outstanding shares.

Versant Venture Capital and Versant Vantage I have reduced their aggregate beneficial ownership in Monte Rosa Therapeutics, Inc. to 4.99% through a series of stock sales and pro rata distributions.

Versant Venture Capital VI, L.P. distributed 744,800 shares of Monte Rosa Therapeutics common stock to its limited partners without additional consideration.

Vestal Point Capital, LP, along with its Chief Investment Officer Ryan Wilder, has reported beneficial ownership of 5.4% of Monte Rosa Therapeutics, Inc. common stock.

T. Rowe Price Associates, Inc. has reported beneficial ownership of 10.5% of Monte Rosa Therapeutics Inc.'s common stock as of June 30, 2026.

Biotechnology Value Fund and its affiliates have reported a 6.3% beneficial ownership stake in Monte Rosa Therapeutics, Inc. as of March 31, 2026.

Dimension Management and associated entities have filed a Schedule 13G reporting an 8.1% beneficial ownership stake in Monte Rosa Therapeutics, Inc.

Dimension Capital I, L.P. and its affiliated entities have reported a beneficial ownership of 8.7% in Monte Rosa Therapeutics, Inc. common stock.

T. Rowe Price Associates, Inc. has filed an amendment to disclose its beneficial ownership of 7.5% of Monte Rosa Therapeutics Inc. common stock.